Clinical trials: Combined Advanced Targeted Therapy
Recurrent Melanoma, Stage IIB Melanoma (Locally Advanced)
Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery
This phase II trial studies how well giving dabrafenib alone and in combination with trametinib before surgery works in treating patients with advanced melanoma that can be removed by surgery.
- Conditions
- Recurrent Melanoma, Stage IIB Melanoma (Locally Advanced), Stage IIC Melanoma (Locally Advanced), Stage IIIA Melanoma
- Trial name
- NCT01701037
- Testing
- dabrafenib, trametinib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Patients With Advanced Solid Tumor, Advanced Solid Tumor With Oncogenic Driver Mutations
A Study of GH21 Combined With Previous Target Therapy or Immunotherapy in Patients With Advanced Solid Tumors
This study is aim to evaluate the preliminary efficacy of GH21 combined with previous target therapy or immunotherapy in patients with advanced solid tumors.
- Trial name
- NCT06322095
- Testing
- PD-1, MET inhibitor, ALK inhibitor
- Where
- 2 sites in China
- Volunteers
- 72 people
- Sponsor
- Suzhou Genhouse Bio Co., Ltd.
Renal Cell Carcinoma, Immunotherapy
Vorolanib Plus Sintilimab for Advanced Renal Cell Carcinoma After Failure of Prior Immune Checkpoint Inhibitors Based Combination Therapy
This Phase II trial assesses Vorolanib and Sintilimab for advanced renal cell carcinoma after previous therapy failure. Participants receive the treatment until disease progression, intolerable side effects, death, or withdrawal.
- Conditions
- Renal Cell Carcinoma, Immunotherapy, Molecular Targeted Therapy
- Trial name
- NCT06523049
- Testing
- Vorolanib Tablets, Sintilimab Injection
- Where
- China
- Volunteers
- 67 people
- Sponsor
- Hao Zeng
Melanoma
A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma
This study will examine the effectiveness and safety of glembatumumab vedotin as monotherapy or in combination with immunotherapies in patients with advanced melanoma.
- Trial name
- NCT02302339
- Testing
- glembatumumab vedotin, glembatumumab vedotin and varlilumab, glembatumumab vedotin and PD-1 targeted checkpoint inhibitor (nivolumab OR pembrolizumab)
- Where
- 14 sites in United States
- Volunteers
- 132 people
- Sponsor
- Celldex Therapeutics
Advanced/Metastatic Head and Neck, Oesophageal and Cervical Cancers
Basket Study to Evaluate the Therapeutic Activity of Simlukafusp Alfa as a Combination Therapy in Participants With Advanced and/or Metastatic Solid Tumors
This is an open-label, multicenter, basket trial Phase II study to evaluate the antitumor activity of simlukafusp alfa in combination with atezolizumab in participants with advanced and/or metastatic solid tumors.
- Trial name
- NCT03386721
- Testing
- simlukafusp alfa, Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody, Gemcitabine
- Where
- 44 sites in United States, Belgium and 13 more
- Volunteers
- 256 people
- Sponsor
- Hoffmann-La Roche
Non-small Cell Lung Cancer, Epidermal Growth Factor Receptor
Targeted Treatment With Intercalated Radiotherapy in EGFR-mutant IIIA/IIIB NSCLC
The aim of this study is to investigate the efficacy and safety of intercalated combination of erlotinib and radiotherapy for patients with EGFR-mutant, unresectable, locally advanced NSCLC, and to explore a new treatment…
- Trial name
- TREND (NCT03074864)
- Testing
- Erlotinib Hydrochloride
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Guangdong Provincial People's Hospital
Gastric Cancer
Immune Combined Targeted and Chemotherapy in Perioperative Treatment of Locally Advanced Gastric Cancer
An exploratory study of pembrolizumab combined with anlotinib and chemotherapy in the perioperative treatment of locally advanced gastric cancer
- Trial name
- ICTCPTLAGC (NCT05385900)
- Testing
- Penpulimab combination with anlotinib and chemotherapy
- Volunteers
- 57 people
- Sponsor
- Xijing Hospital
Breast Cancer
TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called ARV-471) when given together with other medicines for the potential treatment of advanced or metastatic breast cancer.
- Trial name
- NCT05548127
- Testing
- ARV-471, Abemaciclib
- Where
- 37 sites in United States, Canada and 2 more
- Volunteers
- 37 people
- Sponsor
- Pfizer
Solid Tumors
Dasatinib in Combination With Bevacizumab to Treat Advanced Solid Tumors
Background: Bevacizumab inhibits blood vessel growth in cancer cells by blocking a growth factor called VEGF. Dasatinib inhibits the action of proteins called tyrosine kinases, which promote and stimulate blood vessel formation…
- Trial name
- NCT01445509
- Testing
- Bevacizumab, Dasatinib
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Locally Advanced or Metastatic Urothelial Cell Carcinoma, Urinary Bladder Disease
Dose Escalation, Expansion Study of Vofatamab (B-701) in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma
This is a Phase 1/2(b), sequential, dose escalation, open-label, randomized expansion, multicenter, efficacy and safety study of vofatamab alone or in combination with docetaxel, or versus docetaxel in FGFR3 mutant/fusion…
- Conditions
- Locally Advanced or Metastatic Urothelial Cell Carcinoma, Urinary Bladder Disease, Urological Diseases
- Trial name
- FIERCE-21 (NCT02401542)
- Testing
- Vofatamab, Docetaxel
- Where
- 65 sites in United States, Czechia and 7 more
- Volunteers
- 71 people
- Sponsor
- Rainier Therapeutics
Breast Cancer
TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B)
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called ARV-471) when given together with other medicines for the potential treatment of advanced or metastatic breast cancer.
- Trial name
- NCT05573555
- Testing
- ARV-471, Ribociclib
- Where
- 31 sites in United States, Canada and 2 more
- Volunteers
- 20 people
- Sponsor
- Pfizer
Intrahepatic Cholangiocarcinoma
A Study of Liposomal Irinotecan Plus 5-FU/LV HAIC With Lenvatinib and a PD-1 Inhibitor in Advanced ICC
This is a prospective, single-center, single-arm clinical study. It aims to evaluate the efficacy and safety of a new combination therapy as a first-line treatment for patients with advanced intrahepatic cholangiocarcinoma (ICC)…
- Trial name
- NCT07432568
- Testing
- Hepatic Arterial Infusion Chemotherapy (HAIC) with Liposomal Irinotecan, 5-Fluorouracil, Leucovorin, Lenvatinib, PD-1 Inhibitor
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Metastatic Breast Cancer
Exploring Whether Disease-free Intervals Can Guide Endocrine Combined Targeted Therapy for ER+/HER2+ Advanced Breast Cancer (T-sunflower)
This study is a prospective, single-arm, phase II clinical study for patients with ER+/HER2+ advanced breast cancer.
- Trial name
- NCT05577923
- Testing
- Trastuzumab, pyrotinib, Dalpiciclib
- Where
- China
- Volunteers
- 126 people
- Sponsor
- Fudan University
Gastric Cancer
A Real-World Study of Neoadjuvant/Conversion Therapy for Locally Advanced or Metastatic Gastric Cancer
Chemotherapy, immune checkpoint inhibitors, and anti-angiogenic targeted therapies have been explored in combination for neoadjuvant and conversion therapies.
- Trial name
- NCT06464601
- Testing
- fruquintinib combined with immune checkpoint inhibitors and chemotherapy
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Wuhan University
Advanced Solid Tumors
A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors
This is a first-in-human (FIH), open-label, and multi-center Phase I/II study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of CS2009 as Monotherapy and Combination Therapy…
- Trial name
- NCT06741644
- Testing
- CS2009, Pemetrexed, Carboplatin
- Where
- 33 sites in United States, Australia and 1 more
- Volunteers
- 800 people
- Sponsor
- CStone Pharmaceuticals
Intrahepatic Cholangiocarcinoma, Combined Hepatocellular and Cholangiocarcinoma
Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma
This Phase II, open-label, single-arm study evaluated the anti-cancer activity of derazantinib in subjects with inoperable or advanced intrahepatic cholangiocarcinoma (iCCA) who received at least one prior regimen of systemic…
- Trial name
- FIDES-01 (NCT03230318)
- Testing
- derazantinib
- Where
- 41 sites in United States, Belgium and 9 more
- Volunteers
- 148 people
- Sponsor
- Basilea Pharmaceutica
HCC - Hepatocellular Carcinoma, SBRT
Sequential TACE-SBRT Combined With Targeted Immunotherapy for Patients With Intermediate to Advanced Liver Cancer
The goal of this clinical trial is to evaluate whether sequential transarterial chemoembolization (TACE) followed by stereotactic body radiotherapy (SBRT) combined with targeted immunotherapy is effective and safe for patients…
- Conditions
- HCC - Hepatocellular Carcinoma, SBRT, TACE, Immunotherapy
- Trial name
- NCT07230080
- Where
- China
- Volunteers
- 17 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Gastric or Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
This is a first-in-human, Phase 1/2, open-label, dose escalation and dose expansion and combination study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Spevatamig…
- Conditions
- Gastric or Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer (BTC), Colorectal Cancer
- Trial name
- NCT05482893
- Testing
- Spevatamig (PT886), Paclitaxel, Gemcitabine
- Where
- 11 sites in United States
- Volunteers
- 350 people
- Sponsor
- Phanes Therapeutics
Advanced Non-Small Cell Lung Cancer
CALC-1 (Cetuximab in Advanced Lung Cancer): Study of 2 Methods of Combining Cetuximab and Gemcitabine in Patients With Advanced Non Small-cell Lung Cancer
The purpose of this study is to select the more promising method of combining cetuximab with gemcitabine for treating patients with advanced non small-cell lung cancer, who are not candidates for platinum based therapy.
- Trial name
- CALC-1 (NCT00330746)
- Testing
- cetuximab, gemcitabine
- Where
- 25 sites in Italy
- Volunteers
- 100 people
- Sponsor
- National Cancer Institute, Naples
SCCHN
Safety and Efficacy Study of Target Therapy Combined With Radiotherapy to Treat Senile Locally Advanced SCCHN
Radiotherapy alone is generally the only treatment in old patients with SCCHN. No evidence indicates combination with EGFR Target therapy can bring benefit for the patients.
- Trial name
- NCT01393184
- Testing
- Nimotuzumab and Radiotherapy
- Volunteers
- 92 people
- Sponsor
- Peking University